Form 4 for PYXS Pyxis Oncology, Inc.
Accepted 2023-09-22 00:00:00 ET · period of report 2023-09-22 · accession 0001209191-23-050432 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-22 | 2023-09-22 | PYXS | Connealy Pamela Ann | CFO, COO | P - Purchase | $1.74 | +5,000 | 792.1K | +0.6% | +$8,700 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-22 | P | A | 5,000 | $1.74 | 792,106 | D | — | — | (F1) The Reporting Person purchased all 5,000 shares of common stock in the open market at a price of $1.739 per share. |